Latest Retail News

NoviqTech Limited has expanded its sustainability technology footprint through key partnerships in hydrogen and battery recycling, secured a significant grant extension, and announced a $1.25 million capital raise to fuel growth.

Elixinol Wellness reported a 10.8% revenue increase in Q2 2025, supported by improved cash receipts and a focused cost containment program. The company secured new funding and launched a menopause-targeted product, positioning itself for margin growth and profitability in H2.

Michael Hill International reports flat full-year earnings and sales for FY25, with a second-half sales uptick and strategic store closures shaping its outlook.

Skin Elements Limited advances its proprietary SE Formula biotechnology with ECO-Nurture poised for commercial rollout in 2026, alongside progress in disinfectant and sunscreen product lines.

Australian Bond Exchange Holdings (ASX, ABE) reported a stronger Q4 FY25 with participation in a landmark digital currency pilot and the launch of an innovative AUD-denominated market-linked security, alongside improved cash flow and fresh capital raises.

Cann Group Limited delivered record production and revenue growth in Q4 FY2025, securing new funding and advancing a major debt restructuring to set the stage for profitability in FY2026.

Delorean Corporation has marked significant progress in Q4 FY2025, advancing its renewable gas infrastructure and securing crucial regulatory support that could unlock new revenue streams.

Cettire warns that recent US tariff changes removing duty-free exemptions on shipments under $800 could impact nearly half its revenue. The luxury e-commerce platform is evaluating the consequences and adjusting its global strategy.

Orange Minerals NL has begun trading on the U.S. OTCQB Venture Market, enhancing its visibility and liquidity among North American investors while progressing its strategic acquisition of a promising gold project in Ghana.

Starpharma reports a 165% rise in FY25 customer receipts, advances its clinical-stage DEP® assets, and secures new distribution deals in Asia and Saudi Arabia.

MedAdvisor reports a significant revenue decline in FY25 amid US program delays but strengthens its balance sheet through a capital raise and ANZ business sale. The company signals a strategic pivot with potential US business divestment on the horizon.

The Calmer Co. International Limited reported a 6% quarterly revenue increase to $1.9 million in Q4 FY25, driving FY25 revenue to $8.0 million, an 86% year-on-year growth. Key channel expansions and cost efficiencies underpin its progress towards breakeven.